









市场行情
/
股票
/
nasdaq-zyme
/

Zymeworks Inc

ZYME

26.860USD

+0.070+0.26%

收盘 12/24, 13:00（美东）报价延迟15分钟

2.03B总市值

亏损市盈率 TTM



Zymeworks Inc

26.860

+0.070+0.26%

概览公司财务分析

概览

公司

财务

分析

关于 Zymeworks Inc 公司

Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.

Zymeworks Inc简介



公司代码ZYME

公司名称Zymeworks Inc

上市日期Jun 24, 2019

CEOGalbraith (Kenneth H)

员工数量280

证券类型Ordinary Share

年结日Jun 24

公司地址108 Patriot Drive, Suite A

城市MIDDLETOWN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编19709

电话13022748744

网址https://www.zymeworks.com/

公司代码ZYME

上市日期Jun 24, 2019

CEOGalbraith (Kenneth H)

Zymeworks Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Robert E. (Bob) Landry

Independent Director

Mr. Gregory A. Ciongoli

Independent Director

Dr. Kelvin M. Neu ,M.D.

Independent Director

Mr. Scott Platshon

Acting Chief Investment Officer

Dr. Alessandra Cesano, M.D., Ph.D.

Independent Director

Ms. Leone D. Patterson, CPA

Chief Financial Officer, Chief Business Officer, Executive Vice President

Mr. Kenneth H. (Ken) Galbraith

Chairman of the Board, President, Chief Executive Officer

Mr. Carlos E. Campoy

Independent Director

Dr. Susan M. (Sue) Mahony, Ph.D.

Lead Independent Director

Mr. Oleg Nodelman

Independent Director

名称

名称/职务

职务

持股

持股变动

Mr. Robert E. (Bob) Landry

Independent Director

Mr. Gregory A. Ciongoli

Independent Director

Dr. Kelvin M. Neu ,M.D.

Independent Director

Mr. Scott Platshon

Acting Chief Investment Officer

Dr. Alessandra Cesano, M.D., Ph.D.

Independent Director

Ms. Leone D. Patterson, CPA

Chief Financial Officer, Chief Business Officer, Executive Vice President

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

EcoR1 Capital, LLC

30.69%

Rubric Capital Management LP

6.29%

BVF Partners L.P.

5.26%

Morgan Stanley & Co. LLC

5.23%

Redmile Group, LLC

4.95%

其他

47.56%

持股股东

占比

EcoR1 Capital, LLC

30.69%

Rubric Capital Management LP

6.29%

BVF Partners L.P.

5.26%

Morgan Stanley & Co. LLC

5.23%

Redmile Group, LLC

4.95%

其他

47.56%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

51.37%

Investment Advisor

19.68%

Hedge Fund

18.70%

Research Firm

6.53%

Private Equity

2.79%

Individual Investor

0.88%

Pension Fund

0.31%

Venture Capital

0.28%

Sovereign Wealth Fund

0.27%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

390

74.41M

99.43%

-2.56M

2025Q2

383

76.90M

102.73%

+2.83M

2025Q1

400

71.70M

97.61%

-1.37M

2024Q4

389

68.69M

99.73%

-8.79M

2024Q3

388

74.13M

105.03%

-25.13M

2024Q2

387

74.77M

106.29%

-27.88M

2024Q1

389

74.54M

106.20%

-28.73M

2023Q4

388

72.09M

103.65%

-29.69M

2023Q3

376

69.54M

103.06%

-33.91M

2023Q2

364

70.30M

109.70%

-27.74M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

EcoR1 Capital, LLC

22.97M

30.56%

+5.09M

+28.44%

Jun 30, 2025

Rubric Capital Management LP

4.71M

6.27%

+372.11K

+8.58%

Jun 30, 2025

BVF Partners L.P.

4.31M

5.73%

Jun 30, 2025

Morgan Stanley & Co. LLC

3.62M

4.82%

+317.19K

+9.60%

Jun 30, 2025

Redmile Group, LLC

4.15M

5.52%

-638.32K

-13.33%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.11M

4.14%

-287.50K

-8.46%

Jun 30, 2025

The Vanguard Group, Inc.

2.46M

3.27%

+694.76K

+39.45%

Jun 30, 2025

Perceptive Advisors LLC

1.28M

1.7%

-589.40K

-31.61%

Jun 30, 2025

Vestal Point Capital, LP

1.15M

1.53%

+650.00K

+130.00%

Jun 30, 2025

Blackstone Alternative Asset Management, L.P.

1.66M

2.2%

+274.20K

+19.83%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Tema Oncology ETF

2.25%

Virtus LifeSci Biotech Clinical Trials ETF

0.99%

ProShares Ultra Nasdaq Biotechnology

0.24%

iShares Micro-Cap ETF

0.18%

Federated Hermes MDT Small Cap Core ETF

0.15%

WisdomTree US SmallCap Quality Growth Fund

0.15%

SPDR S&P International Small Cap ETF

0.14%

Invesco Nasdaq Biotechnology ETF

0.14%

iShares Biotechnology ETF

0.12%

iShares MSCI USA Small-Cap Min Vol Factor ETF

0.12%

Tema Oncology ETF

占比2.25%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.99%

ProShares Ultra Nasdaq Biotechnology

占比0.24%

iShares Micro-Cap ETF

占比0.18%

Federated Hermes MDT Small Cap Core ETF

占比0.15%

WisdomTree US SmallCap Quality Growth Fund

占比0.15%

SPDR S&P International Small Cap ETF

占比0.14%

Invesco Nasdaq Biotechnology ETF

占比0.14%

iShares Biotechnology ETF

占比0.12%

iShares MSCI USA Small-Cap Min Vol Factor ETF

占比0.12%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Zymeworks Inc的前五大股东是谁？



Zymeworks Inc 的前五大股东如下：
EcoR1 Capital, LLC持有股份：22.97M，占总股份比例：30.56%。
Rubric Capital Management LP持有股份：4.71M，占总股份比例：6.27%。
BVF Partners L.P.持有股份：4.31M，占总股份比例：5.73%。
Morgan Stanley & Co. LLC持有股份：3.62M，占总股份比例：4.82%。
Redmile Group, LLC持有股份：4.15M，占总股份比例：5.52%。